NASDAQ:COCP Cocrystal Pharma (COCP) Stock Price, News & Analysis $2.20 -0.02 (-0.90%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.19▼$2.2250-Day Range$1.89▼$2.8052-Week Range$1.33▼$3.29Volume9,434 shsAverage Volume22,400 shsMarket Capitalization$22.38 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Cocrystal Pharma alerts: Email Address Cocrystal Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside354.5% Upside$10.00 Price TargetShort InterestHealthy0.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.81Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.02) to ($2.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.50 out of 5 starsMedical Sector525th out of 936 stocksPharmaceutical Preparations Industry239th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingCocrystal Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCocrystal Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Cocrystal Pharma's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.50% of the float of Cocrystal Pharma has been sold short.Short Interest Ratio / Days to CoverCocrystal Pharma has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cocrystal Pharma has recently increased by 97.24%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCocrystal Pharma does not currently pay a dividend.Dividend GrowthCocrystal Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for COCP. Previous Next 2.7 News and Social Media Coverage News SentimentCocrystal Pharma has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cocrystal Pharma this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cocrystal Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders25.64% of the stock of Cocrystal Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 6.72% of the stock of Cocrystal Pharma is held by institutions.Read more about Cocrystal Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cocrystal Pharma are expected to decrease in the coming year, from ($2.02) to ($2.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cocrystal Pharma is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cocrystal Pharma is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCocrystal Pharma has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cocrystal Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.Watch Alex's "Next Magnificent Seven" presentation now. About Cocrystal Pharma Stock (NASDAQ:COCP)Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Read More COCP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COCP Stock News HeadlinesJuly 19, 2024 | markets.businessinsider.comCocrystal Pharma Gets Positive Result From Phase 1 Study With CDI-988; Stock UpJuly 19, 2024 | msn.comCOCP: Phase 1 Single-Ascending Dose Cohort of CDI-988 Shows it is Safe and Well Tolerated…July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 16, 2024 | finance.yahoo.comCOCP: Enrollment Complete in Phase 2a Human Challenge Trial of CC-42344…May 13, 2024 | investorplace.comCOCP Stock Earnings: Cocrystal Pharma Beats EPS for Q1 2024May 13, 2024 | globenewswire.comCocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsMay 1, 2024 | finance.yahoo.comEnrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal InfluenzaMay 1, 2024 | globenewswire.comEnrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal InfluenzaJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.April 23, 2024 | finance.yahoo.comCOCP: Topline Data for Influenza A and Dual Coronavirus/Norovirus Programs Expected in 2024; Model Revision Leads to Valuation of $6 Per Share…April 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cocrystal Pharma (COCP) and Icecure Medical (ICCM)March 28, 2024 | msn.comCOCP Stock Earnings: Cocrystal Pharma Beats EPS for Q4 2023March 28, 2024 | finanznachrichten.deCocrystal Pharma, Inc.: Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsMarch 28, 2024 | benzinga.comRecap: Cocrystal Pharma Q4 EarningsMarch 28, 2024 | globenewswire.comCocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsMarch 20, 2024 | finanznachrichten.deCocrystal Pharma, Inc.: Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza AMarch 19, 2024 | markets.businessinsider.comCocrystal Pharma Receives Pre-IND Feedback Regarding CC-42344 - Quick FactsMarch 19, 2024 | globenewswire.comCocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza ASee More Headlines Receive COCP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cocrystal Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:COCP CUSIPN/A CIK1412486 Webwww.cocrystalpharma.com Phone(305) 425-1780FaxN/AEmployees12Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+354.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-61.61% Return on Assets-55.60% Debt Debt-to-Equity RatioN/A Current Ratio10.30 Quick Ratio10.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.59 per share Price / Book0.85Miscellaneous Outstanding Shares10,174,000Free Float7,565,000Market Cap$22.38 million OptionableNot Optionable Beta1.41 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Roger D. Kornberg Ph.D. (Age 77)Co-Founder, Independent Chairman, Chief Scientist & Chairman of Scientific Advisory Board Comp: $130kDr. Sam Lee Ph.D. (Age 64)Co-Founder, Co-CEO & President Comp: $559.82kMr. James J. Martin CPA (Age 57)M.B.A., Co-CEO, CFO & Corporate Secretary Comp: $559.82kKey CompetitorsOncternal TherapeuticsNASDAQ:ONCTCheckpoint TherapeuticsNASDAQ:CKPTTiziana Life SciencesNASDAQ:TLSAAnixa BiosciencesNASDAQ:ANIXEton PharmaceuticalsNASDAQ:ETONView All Competitors COCP Stock Analysis - Frequently Asked Questions How have COCP shares performed this year? Cocrystal Pharma's stock was trading at $1.7222 at the beginning of 2024. Since then, COCP stock has increased by 27.7% and is now trading at $2.20. View the best growth stocks for 2024 here. How were Cocrystal Pharma's earnings last quarter? Cocrystal Pharma, Inc. (NASDAQ:COCP) posted its quarterly earnings results on Monday, May, 13th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.15. When did Cocrystal Pharma's stock split? Shares of Cocrystal Pharma reverse split on the morning of Tuesday, October 11th 2022. The 1-12 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Cocrystal Pharma? Shares of COCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cocrystal Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cocrystal Pharma investors own include Moderna (MRNA), Hello Group (MOMO), Intra-Cellular Therapies (ITCI), Impala Platinum (IMPUY), GenMark Diagnostics (GNMK), Gevo (GEVO) and Auxly Cannabis Group (CBWTF). This page (NASDAQ:COCP) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cocrystal Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cocrystal Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.